BiotechTube

AFQ056 + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dyskinesias

Conditions

Dyskinesias, Parkinson Disease, Movement Disorders, Parkinsonian Disorders

Trial Timeline

Nov 1, 2011 → Sep 1, 2012

NCT ID
NCT01385592

About AFQ056 + Placebo

AFQ056 + Placebo is a phase 2 stage product being developed by Novartis for Dyskinesias. The current trial status is completed. This product is registered under clinical trial identifier NCT01385592. Target conditions include Dyskinesias, Parkinson Disease, Movement Disorders.

What happened to similar drugs?

0 of 1 similar drugs in Dyskinesias were approved

Approved (0) Terminated (0) Active (1)
🔄Levodopa-carbidopa intestinal gelAbbViePhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (11)

NCT IDPhaseStatus
NCT04771143Phase 1Withdrawn
NCT03242928Phase 2Completed
NCT02920892Phase 2Completed
NCT01813019Phase 2Terminated
NCT01491529Phase 2Completed
NCT01385592Phase 2Completed
NCT01357239Phase 2Completed
NCT01253629Phase 2Completed
NCT01019473Phase 2Terminated
NCT00888004Phase 2Completed
NCT00582673Phase 2Completed

Competing Products

4 competing products in Dyskinesias

See all competitors
ProductCompanyStageHype Score
Levodopa-carbidopa intestinal gelAbbViePhase 3
40
AFQ056NovartisPhase 2
35
AFQ056 + PlaceboNovartisPhase 2
35
AQW051 + AQW051 + PlaceboNovartisPhase 2
35